MedTrace Logo

Treatment of Hepatitis c by Using Direct-acting Antiviral

NCT05372874 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-05-13

No results posted yet for this study

Summary

Patients with hepatitis c showed increased level of oxidative stress. Increased level of serum lipid peroxidation leads to the production of toxic mediators as malondialdehyde (MDA) which lead to disease progression. Chronic stress shunt tryptophan which is essential amino acid toward kynurenic pathway leading to lower level of serotonin and melatonin level. Currently, direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV).

Conditions

  • Hepatitis C

Interventions

DRUG

Direct Acting Antivirals

hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sabry A AbouSaif, Professor · Tanta University

  • Sally E Abu-Risha, Associate professor · Tanta University

  • Medhat I Abd-El Hamed, Professor · Faculty of Medicine, Al-Azhar University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-06
Primary Completion
2022-07-12
Completion
2022-07-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05372874 on ClinicalTrials.gov